The purpose of this transmittal is to clarify the coverage of Narcan® (4 milligram naloxone hydrochloride nasal spray), following the recent approval by the U.S. Food and Drug Administration (FDA) to allow the sale of the drug without a prescription, or “over-the-counter” (OTC). Narcan® is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose.